中国肿瘤生物治疗杂志2024，Vol.31Issue(3)：211-218,8.DOI:10.3872/j.issn.1007-385x.2024.03.001
2023年γδT细胞肿瘤治疗领域重大进展
Major progress made in γδT cell-based tumor immunotherapy in 2023
摘要
Abstract
γδT cell is a unique kind of innate immune T cell expressing T cell receptor γ and δ chain heterodimer.There is a lack of comprehensive and systematic basic research in the development,differentiation,proliferation,activation,effect and exhaustion of γδT cell that many main questions are remaining unclear.However,mature γδT cells predominantly colonize mucosal tissues with a high incidence of tumors,such as skin,digestive tract,respiratory tract,and reproductive tract,and can directly recognize and kill a variety of tumor cells without major histocompatibility complex(MHC)restriction,which has irreplaceable advantages in the field of tumor immunotherapy.In recent years,the application of γδT cells have surged and developed rapidly,which,in turn,contributed to the deepening of basic research,and thus some brilliant progress has been made.In this paper,we enumerate the major progress of γδT cells in tumor immunotherapy in 2023,mainly focusing on the mechanism of tumor antigen recognition by γδT cells,the functional regulation of γδT cells in the tumor microenvironment,the mechanism of anti-tumor cytotoxicity of γδT cells,and the new synergistic strategy of tumor immunotherapy based on γδT cells.It is expected to promote the further development of γδT cells in the field of tumour immunotherapy and provide new insights into the synergistic strategy of γδT cells in clinical application.关键词
γδT细胞/免疫治疗/肿瘤Key words
γδT cell/immunotherapy/tumor分类
医药卫生引用本文复制引用
赵跃祺,张建民,陈慧,何维..2023年γδT细胞肿瘤治疗领域重大进展[J].中国肿瘤生物治疗杂志,2024,31(3):211-218,8.基金项目
中国医学科学院创新工程项目(No.2021-I2M-1-035) （No.2021-I2M-1-035）
国家自然科学基金项目(No.32270915,No.U20A20374,No.31970843,No.82071791,No.81972886) （No.32270915,No.U20A20374,No.31970843,No.82071791,No.81972886）
北京市科委中关村管委会创新药方向课题(No.Z221100007922040) （No.Z221100007922040）
国家重点研发计划项目(No.2022YFC3602004) （No.2022YFC3602004）
常州市科技支撑计划项目(No.CE20215008) （No.CE20215008）
